Clinical Trial Update: PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS) [NA]

View source ↗

Summary

The REPRESS study is investigating PCSK9 inhibitors for early stabilization of coronary atherosclerotic plaques in acute coronary syndrome. The trial status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• PCSK9 inhibitors

Snippet

Sponsor: West China Hospital | Conditions: Coronary Artery Disease | NA | Status: NOT_YET_RECRUITING